Eagle Pharmaceuticals, Inc. ("Eagle") (Nasdaq:EGRX) today announced that the Company will release its 2014 second quarter financial results on Wednesday, May 14, 2014, before the market opens.
Following release of the results, the Company will host a conference call at 9:30 a.m. Eastern Daylight Time. Scott Tarriff, President and Chief Executive Officer, and David E. Riggs, Chief Financial Officer, will conduct the call.
Interested parties may participate in the conference call by dialing 866-952-1906 (US), or 785-424-1825 (International), 5-10 minutes prior to the start of the call. A replay of the conference call will be available for two weeks after the call's completion by dialing 866-952-1906 (US) or 785-424-1825 (International) and entering conference call ID number EGRXQ214.
A live audio webcast and archive will also be available for 30 days under the “Investor Relations” section of the Eagle website at www.eagleus.com.
ABOUT EAGLE
Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products utilizing the FDA's 505(b)(2) regulatory pathway. The Company develops products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Additional information is available on the company’s website at eagleus.com.
Eagle Pharmaceuticals, Inc.
David E. Riggs
Chief Financial Officer
T: 201-326 5300
E: driggs@eagleus.com
or
In-Site Communications, Inc.
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com